Quantitative CT Evaluation of Bronchiectasis Improvement in Cystic Fibrosis after CFTR-Modulator Therapy
Abstract
Purpose: To assess whether elexacaftor–tezacaftor–ivacaftor (ETI) therapy improves bronchiectasis in cystic fibrosis at CT and to identify associated factors. Materials and Methods: This retrospective study included consecutive patients with cystic fibrosis (CF) from two reference centers (between January 2020 and January 2025). Pulmonary function testing was performed, including forced expiratory volume in 1 second as percentage predicted (FEV1%p), and CT was performed at three time points: 2 years before ETI (Y-2), at initiation of ETI (Y0), and 1 year after ETI (Y1). Bronchiectasis was assessed quantitatively and visually for shape and regional extent. Comparisons of paired medians were done using the Friedman test. Results: A total of 106 patients were included (median age, 19 years [IQR, 12–29]; 59 male patients; median FEV1%p, 80% [IQR, 55–99]). Of these 106 patients, 101 (95.3%) had mild-to-moderate disease severity, with FEV1%p greater than 40%. Bronchiectasis normalized volumes increased between Y-2 (7.6 [IQR, 2–19]) and Y0 (15.3 [IQR, 5.6–32]) but decreased at Y1 (3.6 [IQR, 0.6–25]; P < .001). Bronchiectasis improved in 74 of 106 patients (69.8%), including 18 of 106 (16.9%) with complete resolution and 56 of 106 (52.9%) with partial reduction, with a median volume reduction of 64% and six resolved segments per patient. Bronchiectasis improvement was associated with younger age (P < .001), cylindric CT pattern (P < .001), fewer CT abnormalities (P < .001), and greater FEV1%p increase (P = .03). Younger age, lower Pseudomonas aeruginosa colonization, and lower CT mucus volume were independent predictors of bronchiectasis improvement (R2 = 0.50; P < .001). Conclusion: Bronchiectasis improvement occurred after ETI treatment in a substantial fraction of patients with predominantly mild-to-moderate CF. Improvement was linked to younger age and better disease status at ETI initiation, supporting early intervention
Related
- Machine learning quantitative OCT derived fibrosis indicators for corneal haze evaluation
- Combining Gene Therapy with Current Modulator Treatments for Cystic Fibrosis: A Promising Area of Research
- Microscopy Image Dataset of pulmonary vessels for Quantitative assessment of fibrosis
- Multi-parametric NIR-II fluorescence perfusion imaging towards quantitative stroke evaluation
- Comparing attenuation parameter and liver stiffness measurement using Hepatus and Fibroscan for the evaluation of steatosis and fibrosis in patients with chronic liver disease: A prospective study
BibTeX
@article{bouzid2026quantitative,
title = {{Quantitative CT Evaluation of Bronchiectasis Improvement in Cystic Fibrosis after CFTR-Modulator Therapy}},
author = {Amel Imene Hadj Bouzid and Daphné Pasche and Ilyes Benlala and Stéphanie Bui and Julie Macey and Jean Delmas and Fabien Beaufils and Baudouin Denis de Senneville and Patrick Berger and Gaël Dournes},
journal = {Radiology: Cardiothoracic Imaging},
year = {2026},
month = oct,
doi = {10.1148/ryct.250116},
url = {https://hal.science/hal-05805896v1},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Quantitative CT Evaluation of Bronchiectasis Improvement in Cystic Fibrosis after CFTR-Modulator Therapy
AU - Amel Imene Hadj Bouzid
AU - Daphné Pasche
AU - Ilyes Benlala
AU - Stéphanie Bui
AU - Julie Macey
AU - Jean Delmas
AU - Fabien Beaufils
AU - Baudouin Denis de Senneville
AU - Patrick Berger
AU - Gaël Dournes
PY - 2026
DA - 2026/10/20
JO - Radiology: Cardiothoracic Imaging
DO - 10.1148/ryct.250116
UR - https://hal.science/hal-05805896v1
AB - Purpose: To assess whether elexacaftor–tezacaftor–ivacaftor (ETI) therapy improves bronchiectasis in cystic fibrosis at CT and to identify associated factors. Materials and Methods: This retrospective study included consecutive patients with cystic fibrosis (CF) from two reference centers (between January 2020 and January 2025). Pulmonary function testing was performed, including forced expiratory volume in 1 second as percentage predicted (FEV1%p), and CT was performed at three time points: 2 years before ETI (Y-2), at initiation of ETI (Y0), and 1 year after ETI (Y1). Bronchiectasis was assessed quantitatively and visually for shape and regional extent. Comparisons of paired medians were done using the Friedman test. Results: A total of 106 patients were included (median age, 19 years [IQR, 12–29]; 59 male patients; median FEV1%p, 80% [IQR, 55–99]). Of these 106 patients, 101 (95.3%) had mild-to-moderate disease severity, with FEV1%p greater than 40%. Bronchiectasis normalized volumes increased between Y-2 (7.6 [IQR, 2–19]) and Y0 (15.3 [IQR, 5.6–32]) but decreased at Y1 (3.6 [IQR, 0.6–25]; P < .001). Bronchiectasis improved in 74 of 106 patients (69.8%), including 18 of 106 (16.9%) with complete resolution and 56 of 106 (52.9%) with partial reduction, with a median volume reduction of 64% and six resolved segments per patient. Bronchiectasis improvement was associated with younger age (P < .001), cylindric CT pattern (P < .001), fewer CT abnormalities (P < .001), and greater FEV1%p increase (P = .03). Younger age, lower Pseudomonas aeruginosa colonization, and lower CT mucus volume were independent predictors of bronchiectasis improvement (R2 = 0.50; P < .001). Conclusion: Bronchiectasis improvement occurred after ETI treatment in a substantial fraction of patients with predominantly mild-to-moderate CF. Improvement was linked to younger age and better disease status at ETI initiation, supporting early intervention
SN - 2638-6135
ER -